How I Treat High-Risk Patients with Essential Thrombocythemia or Polycythemia Vera
Risk stratification in essential thrombocythemia (ET) and polycythemia vera (PV) is critical for estimating the likelihood of vascular events and disease transformation, and for guiding treatment options. This session will review prognostic risk models for ET and PV, as well the historical and contemporaneous data that have informed the selection of cytoreductive therapies for these myeloproliferative neoplasms. Dr. Gotlib will discuss the role of hydroxyurea, [PEG]-interferon-α, and Ruxolitinib, and will highlight the new NCCN management algorithms for PV and ET.
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members